10 results about "Drug overdose" patented technology

Methods and compositions are provided for treating individuals exhibiting opioid withdrawal symptoms with opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of opioid withdrawal symptoms, including respiratory depression, sedation, and hypotension. Methods and compositions are also provided for treating stimulant overdose with a benzodiazepine and beta-adrenergic blocking agent. Methods and compositions are also provided for treating concurrent stimulant and opioid overdose comprising administering to a patient in need thereof a benzodiazepine and an opioid antagonist. Methods and compositions are also provided for treating individuals exhibiting opioid withdrawal symptoms or prophy tactically treating individuals for opioid withdrawal symptoms from opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of withdrawal, including respiratory depression, sedation, and hypotension.

The application provides a non-contact pain monitoring mattress and system based on multi-modal physiological signal fusion, the mattress body comprises, from bottom to top, a bottom support layer, a signal shielding layer, a sensing core layer and a breathable skin-friendly layer, the system comprises the non-contact pain monitoring mattress, a low-noise charge amplifier, a fiber demodulator, an edge computing gateway and a cloud analysis center, the data after signal conditioning is transmitted to the edge computing gateway and uploaded to the cloud analysis center, and the cloud analysis center performs quantitative scoring through a tumor-specific pain model.The application has the advantages that no electrode or wearable device needs to be pasted, the skin irritation and psychological burden of traditional monitoring are completely eliminated, the patient compliance is improved, the limitation of subjective evaluation is broken through, an objective pain evaluation method is provided for patients in the late stage / aphasia, multi-modal signal fusion monitoring is used to effectively distinguish pain from ordinary emotional fluctuations, the degree of pain is fed back in real time, the doctor is assisted in dynamically adjusting the dose of analgesic drugs, and the risk of drug overdose and deficiency is reduced.

The invention system is a wearable device that detects an impending or onset of cardio-respiratory arrest and remediates the condition by injecting an appropriate reversal drug depending upon the drug that triggered the arrest. It can detect and remediate arrests caused by drugs such as opioids, benzodiazepine or alcohol. Using self-test and other checks, it ensures that the system is operationally ready and that no near-expiration or expired drug is administered.

Briefly, an injection delivery system is described for subcutaneous or intramuscular injection of a drug, in particular a large volume of a biologic drug, high and low viscosity biologies, or a large volume of a high viscosity and low viscosity chemical drug. The injections may be self-administered or performed by a caregiver. The system uses a pump to move a drug from a vial, thorough an infusion set, and into the patient. A vial of a biological or chemical drug is set into a vial adapter that is associated with the pump, which can be manual or powered. A fluidics subassembly connects the vial adapter, pump, and the infusion set so that a drug pathway is enabled from the vial to the patient. The fluidics subassembly has one or more check valves to assure that the drug pathway is only enabled for a one-way drug flow out of the vial and to the patient. The infusion set has flexible tubing that connects the fluidics subassembly to cannula assembly inside an infuser housing. The cannula assembly has an air evacuation assembly near the tip of the needle. This air evacuation assembly is constructed to safely exhaust air from the cannula assembly at three times: (1) at initial setup to exhaust air while the drug is filling the cannula assembly, which enables the self-priming; (2) during injection to exhaust drug-entrapped air, which increases injection safety; and (3) at the end of drug delivery to exhaust air after the full dose of drug has been delivered to the cannula assembly, including drug that was in the tubing, which reduces wasted drug and minimizes the amount of drug overfill required in the vial.

A method, apparatus and computer program product are provided for a compiled standardized measure representative of a subset of prescription transactions associated with a controlled substance. The compiled standardized measures may be used in the prescription domain to notify prescribers of a patient's morphine milligram equivalent (MME) to reduce risks related to drug overdose, abuse, and the like. Historical prescription transactions may be accessed to identify prescriptions classified as an opioid or other controlled substance, and that may likely still be in a patient's possession based upon days supply, such that a daily MME may be calculated. Messaging is provided to the prescriber if the amount exceeds a maximum threshold, and the prescription can be changed accordingly.

In some embodiments, the present invention discloses a method for treating drug overdose, comprising administering a therapeutically effective amount of a respiratory stimulant to a patient in need, wherein the overdose drug comprises an α2-adrenergic receptor agonist.

The application discloses a TENS and iontophoresis composite closed-loop analgesic patch, and belongs to the field of medical devices. The patch comprises a flexible substrate, a multi-modal sensor array, a transcutaneous electrical nerve stimulation unit, an iontophoresis drug delivery unit, a control module and a multi-level safety control unit. The sensor array collects surface electromyography signals and cutaneous electric response signals, and the control module calculates a pain probability value and executes a hierarchical control strategy: standby when the pain probability value is below a first threshold value, only activate the TENS unit when the pain probability value reaches or exceeds the first threshold value but is below a second threshold value, and simultaneously activate the TENS unit and the iontophoresis drug delivery unit after dose safety confirmation when the pain probability value reaches or exceeds the second threshold value. The multi-level safety control unit comprises a dose counter and a sensor detachment detection module, which are used for preventing drug overdose and accidental triggering. The application combines physical analgesia and chemical analgesia, realizes double analgesic effects of "instant + continuous", and guarantees the safety of home use through a multi-level safety mechanism.

The application provides a digoxin microtablet and a preparation method thereof. The digoxin microtablet prepared by the application contains 5-100 micrograms of digoxin per tablet, which can meet the dosage requirements of patients of different ages, realize precise dosage administration, and reduce the risk of drug overdose in clinical application. The digoxin microtablet provided by the application can solve the problem that infants and children have difficulty in swallowing the medicine, thereby improving the medication compliance of infants and children. Compared with conventional tablets, the microtablet has a smaller volume. The digoxin microtablet provided by the application is prepared by optimizing the prescription and process, preparing a digoxin compound by a spray drying and hot melt extrusion technology, obtaining a solid dispersion, and having better content uniformity and dissolution rate, and significantly improving the bioavailability.

Provided is a drug vaporization and inhalation device. The drug vaporization and inhalation device is configured such that when a user inhales a particulate drug, the drug is contained in vaporized steam, and therefore, the drug can sufficiently arrive at the lungs of the user, without loss, thereby preventing a given amount of the drug from remaining in an inhalation container and improving the drug inhalation efficiency of the user along with prevention of excessive inhalation of the drug.

The invention discloses a method for detecting the concentration of tacrolimus by using a photonic crystal microarray immunosensor, and mainly relates to the field of blood concentration detection. Comprising the following steps: S1, manufacturing a photonic crystal chip; s2, treating the blood sample; s3, combining the photonic crystal chip prepared in the step S1 with a portable fluorescence detector; and S4, quantitatively detecting the concentration of tacrolimus in the blood sample treated in the step S2 by using the portable fluorescence detector combined in the step S3. The invention has the beneficial effects that the unique structure of the photonic crystal is utilized to enhance a fluorescence signal, the detection sensitivity and the detection limit are effectively improved, the detection time is shortened, the operation is simple and convenient, the detection cost is reduced, and the method can be widely applied to drug concentration monitoring of organ transplantation patients and prevention of side effects caused by rejection reaction and excessive drug.